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L-selectin, a lectin-like receptor on all leukocyte classes, functions in adhesive and signaling roles in the
recruitment of myeloid cells from the blood to sites of inflammation. Here, we consider L-selectin as a determinant
of neurological recovery in a murine model of spinal cord injury (SCI). Spinal cord-injured, L-selectin knock-out
(KO) mice (male) showed improved long-term recovery with greater white matter sparing relative to wild-type (WT)
mice and reduced oxidative stress in the injured cord at 72 h post-SCI. There was a partial and transient reduction
in accumulation of neutrophils in the injured spinal cords of KOs at 24 h post-injury. To complement these findings
with KO mice, we sought a pharmacologic means for lowering L-selectin levels. We found that diclofenac, a
nonsteroidal anti-inflammatory drug (NSAID), induced the shedding of L-selectin from the cell surface of myeloid
subsets, specifically neutrophils and non-classical monocytes, in the blood and the injured spinal cord. Diclofenac
administration to injured WT mice enhanced neurological recovery to a level comparable to that of KOs but did
not improve recovery in KOs. While diclofenac treatment had no effect on myeloid cell accumulation, there was
a reduction in oxidative stress at 72 h post-SCI. These findings implicate L-selectin in secondary pathogenesis
beyond a role in leukocyte recruitment and raise the possibility of repurposing diclofenac for the treatment of SCI.
Key words: diclofenac; L-selectin; leukocytes; myelin; oxidative stress; spinal cord injury
Introduction
Spinal cord injury (SCI) results in partial or complete
loss of motor and sensory function below the site of injury.
The neurologic deficits resulting from SCI are not solely
attributed to the initial mechanical damage, and there is a
broad consensus that early infiltrating leukocytes, primar-
ily myeloid lineage cells (i.e., neutrophils and monocytes),
release neurotoxic substances including reactive oxygen
species (ROS), proteases, and proinflammatory cytokines
that cause secondary tissue damage (Chatzipanteli et al.,
2002; Noble et al., 2002; Bareyre and Schwab, 2003;
David and Kroner, 2011). Various strategies, directed at
attenuating the early recruitment of myeloid cells from the
blood into the injured spinal cord, have shown promising
results for reducing cell injury and improving long-term
neurologic outcomes (Popovich et al., 1999; Gris et al.,
2004; Popovich and Longbrake, 2008; Lee et al., 2011;
Zhang et al., 2011). However, inconsistent benefits or
deleterious consequences have been observed in other
studies (Stirling et al., 2009; Hurtado et al., 2012). These
discrepancies may be due to opposed reparative and
damaging activities in the targeted myeloid subsets. In the
present study, we have identified L-selectin, a leukocyte
adhesion/signaling receptor, as a novel therapeutic target
in SCI.
Selectins are C-type lectins that generally function se-
quentially with integrins during the multistep process of
leukocyte recruitment from the blood into sites of inflam-
mation (Ley et al., 2007; McEver, 2015). The vascular
selectins, E- and P-selectin, are upregulated on inflamed
vascular endothelium and bind to ligands such as
P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes
(McEver, 2015). L-selectin (CD62L) on lymphocytes me-
diates their rolling on high endothelial venules during
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Significance Statement
In this study, we establish L-selectin, an adhesion and signaling receptor on immune cells, as a determinant
of long-term recovery and tissue sparing after spinal cord injury (SCI). We demonstrate that L-selectin
contributes to secondary pathogenesis during acute inflammation, and implicate L-selectin in novel roles
other than recruitment. We also report a strategy to improve recovery by employing diclofenac, an
FDA-approved nonsteroidal anti-inflammatory drug (NSAID) that induces the shedding of L-selectin from
the surface of innate immune cells. Our findings demonstrate a critical time-period for anti-inflammatory
intervention in a murine model of SCI and suggest that diclofenac be tested as an acute therapy for
attenuating neurologic deficits following SCI in humans.
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homing to secondary lymphoid organs through the inter-
action of its lectin domain with carbohydrate-based li-
gands on this specialized endothelium (Rosen, 2004).
L-selectin is also broadly expressed on circulating my-
eloid leukocytes and has adhesive and signaling activities
that underlie various responses of these cells to inflam-
mation (Ley et al., 2007; McEver, 2015). Studies employ-
ing knock-out (KO) mice or blocking antibodies have
demonstrated that L-selectin, working in concert with
vascular selectins, is involved in the recruitment of my-
eloid cells from the blood into various sites of inflamma-
tion (Lewinsohn et al., 1987; Pizcueta and Luscinskas,
1994; Tedder et al., 1995; Ley et al., 2007; Zuchtriegel
et al., 2015).
It is now clear that L-selectin contributes to myeloid cell
recruitment as a secondary adhesion molecule that me-
diates tethering between endothelial-adherent leukocytes
and circulating leukocytes, via binding in trans to PSGL-1
on leukocytes (Walcheck et al., 1996; Sperandio et al.,
2003), and as a signaling molecule that augments the
activation of integrins on rolling leukocytes (Stadtmann
et al., 2013; Morikis et al., 2017). Additional activities,
apart from the recruitment of leukocytes from the blood,
are indicated in that the ligation of L-selectin on neutrophils by
soluble carbohydrate ligands, such as carcinoma-derived or
salivary mucins, potentiates the degranulation of these cells
(Shao et al., 2011; Mohanty et al., 2015). In the context of
CNS inflammation, the possibility of a post-recruitment
role for L-selectin has emerged based on the observation
that L-selectin mediates the in vitro adhesion of leuko-
cytes to myelinated fiber tracts in the CNS (Huang et al.,
1991, 1994). In light of its potential recruitment and post-
recruitment activities, we have investigated whether the
reduction of L-selectin function through genetic or phar-
macologic means has an impact on neurologic recovery in
a murine model of SCI.
We demonstrate that complete L-selectin deficiency re-
sults in a partial reduction of neutrophil accumulation and
oxidative stress in the acutely injured cord as well as im-
proved long-term neurologic recovery that corresponds to
greater sparing of white matter. We further show that di-
clofenac, an nonsteroidal anti-inflammatory drug (NSAID)
and an inducer of L-selectin shedding from the leukocyte
cell surface (Díaz-González et al., 1995; Gómez-Gaviro et al.,
2002), has beneficial effects in SCI comparable to the ge-
netic elimination of L-selectin. Since diclofenac is currently
approved by the FDA (Altman et al., 2015), there could be an
opportunity to repurpose this drug for the spinal cord-injured
patient. The beneficial consequences of reducing L-selectin
levels cannot be attributed solely to reduced leukocyte re-
cruitment, particularly in the case of diclofenac, highlighting
the consideration of L-selectin in novel roles in secondary
pathogenesis and subsequent long-term neurologic deficits.
Materials and Methods
Animals
These studies were approved by the Institutional Animal
Care and Use Committee at the University of California
San Francisco and were in accordance with the United
States Department of Agriculture guidelines. Homozy-
gous L-selectin KO mice and their wild-type (WT) litter-
mates were generated by breeding heterozygous males
and females on a C57Bl/6 background. We confirmed that
mice from L-selectin KO and WT colonies did not contain
the recently reported copy number variant in the Dock2
allele (Mahajan et al., 2016). WT and KO littermates were
then studied with the exception of flow cytometry exper-
iments where WTs were purchased from The Jackson
Laboratory. WT mice for diclofenac studies were pur-
chased from Jackson Laboratories. Mice were housed in
groups of two to five before injury and singly housed after
SCI.
SCI
Adult male mice (approximately three to five months of
age) were anesthetized with 2.5% Avertin (0.02 ml/g body
weight, i.p., tribromoethanol; Sigma) or 2% isoflurane and
subjected to a spinal cord contusion injury as described
previously (Lee et al., 2011). Briefly, a laminectomy was
performed at the ninth thoracic vertebra and a 3-g weight
was dropped 5–7.5 cm onto the exposed dura mater to
produce the SCI. After injury, the skin was closed with
wound clips. Body temperature was maintained at 37°C
with a warming blanket throughout the surgery and during
recovery from anesthesia. Postoperative care included
subcutaneous administration of saline and antibiotics
daily for 10 d and manual expression of the bladder twice
per day until euthanasia.
Treatment with diclofenac
Diclofenac (Sigma) was dissolved in PBS at 2.5 mg/ml
and sterile filtered before use. To determine whether
diclofenac modulates neurologic recovery after SCI, di-
clofenac (20, 30, or 40 mg/kg) was administered intraperi-
toneally immediately, 3 h, or 8 h after SCI. The dosing was
based on previous studies in rodents (Grace et al., 2001).
Behavioral tests were performed as described below.
Assessment of neurologic recovery
Two behavioral tests, Basso Mouse Scale (BMS) and
grid walk, were performed in the same mice to evaluate
functional improvements after SCI. The nine-point BMS
was used to examine locomotor recovery in an open field
(53  108  5.5 cm; Basso et al., 2006). This rating scale
takes into account limb movement, stepping, coordina-
tion, and trunk stability. Mice were tested at 1, 3, and 7 d
and weekly thereafter until euthanasia at five to six weeks
post-SCI. For studies examining diclofenac in WTs, mice
achieving a BMS score 1 at 1 d post-SCI were consid-
ered insufficiently injured and were removed from the
analysis. For grid walking, a mouse (with a BMS score of
four or greater) was positioned on a grid, divided into
0.5-cm squares, and the number of foot faults was re-
corded over a period of 3 min. A foot fault was evident
when a paw fully extended through a space in the grid.
The grid walking test was performed over 3 d at approx-
imately five weeks post-SCI with three trials per day.
Measurement of white matter sparing
Animals were euthanized at 35 or 42 d post-SCI and
perfused with 50 ml of PBS followed by 50 ml of 4%
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paraformaldehyde (pH 7.4). The spinal cords were re-
moved, postfixed overnight, and cyroprotected in 30%
sucrose for 4 d. Cords were then embedded and frozen at
-80 °C until sectioning; 20-m transverse sections were
made on a cryostat, and serial sections, 500 m apart,
were chosen for staining of white matter using either luxol
fast blue (LFB) or eriochrome cyanine. Sections were
evaluated by light microscopy and the one with the least
spared white matter was selected as the lesion epicenter.
For sections stained with LFB, the area of residual white
matter was hand-traced using Neurolucida software (Mi-
crobrightfield Bioscience) and the percentage of spared
white matter relative to the total cross sectional area of
the cord at the epicenter was determined (Lee et al.,
2011). This epicenter measurement has previously been
demonstrated to correlate with injury severity and the
degree of functional recovery (Kuhn and Wrathall, 1998).
For sections stained with eriochrome cyanine, the area of
residual white matter at the epicenter was traced and
quantified using the StereoInvestigator (MBF Bioscience)
Cavalieri probe.
Immunoblotting
A 0.5 cm length of cord, centered over the site of
impact and representing the epicenter, was homogenized
in Glo lysis buffer (Promega) or RIPA buffer (Thermo
Fisher). The protein concentration in homogenates was
determined by the BCA protein assay kit (Pierce). For
detecting malondialdehyde (MDA), we used the OxiSelect
Malondialdehyde immunoblot kit (Cell BioLabs, Inc.) ac-
cording to the manufacturer’s protocol. Briefly, 20 g of
protein was loaded onto 12–15% SDS-PAGE gel and
transferred onto a nitrocellulose or PVDF membrane. After
blocking the membrane with 1% BSA solution, the mem-
brane was incubated with rabbit anti-MDA antibody over-
night. The membrane was washed with Tris-buffered
saline including 0.1% triton X-100 and then incubated
with anti-rabbit-HRP antibody for 1 h. MDA-positive
bands were detected using Pierce SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientific).
Bands at 65 kDa, including both bands for uninjured
(UN) control samples, were measured. For all of the com-
parisons, -actin (Sigma, RRID:AB_476744) or GAPDH
(Millipore, RRID:AB_2107426) served as a loading control
and was used for normalization.
Cell isolation and treatments
Neutrophils were isolated from peripheral blood of mice
by Ficoll-Paque (Ficoll-Paque PREMIUM 1.084, GE
Healthcare Bio-Sciences AB) according to manufacturer’s
protocol. Briefly, 2 ml of peripheral blood were obtained
by cardiac puncture from three mice and mixed with 10 ml
of HBSS. After addition of 3 ml of Ficoll-Paque, the sam-
ple as subjected to density-gradient centrifugation of 30
min at 400  g at room temperature (RT). Neutrophils
were carefully collected from upper layers. To purify the
neutrophil-enriched fraction, erythrocytes were lysed with
RBC lysis buffer at RT (eBioscience). The purity of the
neutrophil fraction was 90%.
To investigate whether NSAIDs induce L-selectin shed-
ding, the isolated cells were treated with NSAIDs as pre-
viously described (Gómez-Gaviro et al., 2002). Cells were
resuspended in PBS and incubated either alone or in the
presence of diclofenac (20–500 g/ml) or meclofenamic
acid (MFA; 20–500 g/ml, Sigma) for 30 min at 37°C.
PMA (250 ng/ml) served as a positive control. All NSAIDs
were dissolved in PBS. Then cells were analyzed by flow
cytometry and the supernatants were analyzed for soluble
L-selectin (sL-selectin) by enzyme-linked immunosorbent
assay (sL-selectin ELISA section). Data were collected
from seven independent experiments for flow cytometry
and two independent experiments for ELISA.
Flow cytometry
For neutrophils and mononuclear cells exposed to
NSAIDs, the cells were washed with PBS then incubated
with anti-mouse CD16/32 Fc blocking antibody (1:10 di-
lution; eBioscience, RRID:AB_467133) for 10 min followed
by anti-CD62L Ab conjugated with PE (1:10 dilution,
Mel-14 clone, eBioscience, RRID:AB_465720) for 30 min
at 4°C. After washing in PBS, the cells were analyzed in a
FACScan flow cytometer (Becton Dickinson) and FlowJo
software (Tree Star Inc.). In all in vitro experiments, at least
106 cells were analyzed for flow cytometry. Cell viability
was determined by 7-amino-acinomycin D staining (7-
AAD; BD Bioscience). Data were collected from seven
independent experiments.
For in vivo experiments, blood samples were obtained
by cardiac puncture using a heparin-primed syringe from
uninjured and spinal cord-injured mice. Recruitment of
leukocytes from the blood into spinal cord can occur
across blood vessels in the meninges or parenchymal
tissue (Ransohoff et al., 2003). Injured mice were perfused
with 25 ml of ice cold PBS to remove free leukocytes
within blood vessels. From each animal, a 5-mm region of
spinal cord (with associated meninges) centered over the
injury site was removed and stored in ice cold RPMI
media. The spinal cord segment was then mechanically
dissociated using a plastic tissue pestle. The suspension
was filtered through a 100-m nylon mesh filter, and the
filtrate was centrifuged at 300  g, 4°C for 5 min. Blood
and spinal cord samples were then lysed with 1 ml of 1
RBC lysis buffer (eBioscience) for 5 min at 4°C, followed
by the addition of 10 ml of FACS buffer (0.5 M EDTA, 2%
fetal bovine serum, and HBSS; pH 7.4). The cell suspen-
sion was centrifuged and the pellet was re-suspended in
10 ml of HBSS and centrifuged again. Live/dead cell
staining was then performed by incubating samples with
Ghost Dye Red 780 (1:1000, Tonbo Biosciences) for 30
min at 4°C. Samples were washed with 10 ml of FACS
buffer, centrifuged, and the supernatant was discarded.
Cells were then resuspended in FACS buffer and incu-
bated with anti-mouse CD16/32 Fc blocking antibody
(1:100 dilution; eBioscience, RRID:AB_467133) at 4°C for
20 min. Next, samples were washed with 10 mL of FACS
buffer and 1 ml was partitioned for isotype control
staining. Samples were then centrifuged and the pellets
were incubated with a cocktail of the following antibo-
dies: FITC-conjugated rat anti-mouse CD62L (1:100 dilu-
tion, Mel-14 clone, BioLegend, RRID:AB_313093), Pacific
Blue-conjugated rat anti-mouse Ly-6G (1:200 dilution,
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1A8 clone, BioLegend, RRID:AB_2251161), APC-con-
jugated rat anti-mouse CD11b (1:200 dilution, M1/70
clone, BioLegend, RRID:AB_312795), PE-conjugated rat
anti-mouse CD45 (1:200 dilution, 30-F11 clone, Tonbo,
RRID:AB_2621763), and PerCP/Cy5.5-conjugated rat
anti-mouse Ly-6C (1:600 dilution, HK1.4 clone, BioLeg-
end, RRID:AB_1659241). FITC-conjugated rat IgG2a, 
(1:100 dilution, BioLegend, RRID:AB_2736919) served as
the isotype control for CD62L. After incubating with anti-
bodies for 30 min at 4°C, samples were washed with
FACS buffer, centrifuged, and the pellets were resus-
pended in 200 l of FACs buffer. Flow cytometry was
performed on the cell suspensions using a Fortessa flow
cytometer (Becton Dickinson).
The data were analyzed using FlowJo software. At least
50,000 events were analyzed for blood samples, and all of
the collected events were analyzed for spinal cord sam-
ples. Cells (low SSC, high FSC) were gated from debris
(high SSC, low FSC) as previously described (Stirling and
Yong, 2008). The geometric mean fluorescent intensity
(G-MFI) values for CD62L were calculated to determine
the overall presence of L-selectin on the surface of
leukocytes. Since staining histograms for L-selectin
were often skewed, we used G-MFI instead of arithme-
tic MFI to represent the data. This parameter better
reflects the central tendency of skewed distributions.
Isotype G-MFI were determined for each sample and
subtracted from the reported G-MFI values. Total leu-
kocyte and myeloid lineage subset counts from spinal
cord samples were extrapolated to the total volume of
cells to account for the volume of cells removed for
isotype staining.
sL-selectin ELISA
To determine whether diclofenac treatment induces
L-selectin shedding, blood was obtained by cardiac
puncture at 0, 2, 8, 24, and 48 h after intraperitoneal
administration of this drug (1, 5, 10, 20, 40, or 60 mg/kg)
immediately following SCI produced by dropping a 2 g
weight from a distance of 5 cm. After centrifugation at
2000  g for 20 min at RT, plasma was then collected for
assessment using an ELISA kit (Quantikine, mouse sL-
Selectin, R&D Systems) according to the manufacturer’s
instructions. All incubations were conducted at RT and for
2 h unless otherwise indicated. A total of 100 l of super-
natants was first incubated with assay diluent buffer in a
microplate. After rinsing, the preparation was then incu-
bated in 100 l of sL-selectin conjugate, followed by
addition of 100 l of substrate for 30 min. The reaction
was then stopped by addition of stop solution. Optimal
density was read at 450-nm wavelength with correction at
540 nm using a microplate reader (Invitrogen).
Experimental design and statistical analyses
The primary goal of this study was to determine
whether L-selectin contributes to inflammation and neu-
rologic deficits following SCI. We employed L-selectin KO
mice and also evaluated the effect of diclofenac, an
NSAID that induces L-selectin shedding, on inflammation
and neurologic recovery after SCI (Table 1). For all stud-
ies, only adult male mice were used to eliminate gender as
a variable. Time points for collection of data and experi-
mental endpoints were predetermined based on previous
experience. Sample sizes were determined by our previ-
ous experience with BMS scoring and immunoblotting
(Lin et al., 2007; Lee et al., 2011; Whetstone et al., 2017),
and by power analyses for flow cytometry studies and
sL-selectin assays (effect sizes were 500 G-MFI units and
550 ng/ml, respectively, based on our own preliminary
studies). For all studies, we anticipated a 10% mortality
rate, based on previous experience in our lab (Whetstone
et al., 2017) and substantiated in Figure 10I, and we
adjusted the samples sizes accordingly. To control for
potential variation in the SCI surgery and behavioral anal-
yses, all studies were conducted with the surgeon and
observers blinded to the genotype and/or experimental
condition. Simple or block randomization was used for all
in vivo studies.
Statistical analyses were performed using GraphPad
Prism (GraphPad Software). Flow cytometry was evalu-
ated by unpaired two-tailed Student’s t tests or one-way
ANOVA followed by Tukey’s post hoc test. ELISA data
were evaluated by one-way ANOVA followed by a Dun-
nett’s post hoc test. A two-way, repeated measures
ANOVA followed by Sidak’s multiple comparisons test
was used to evaluate BMS scores. Comparison of two
groups (foot faults, spared white matter, and immuno-
blots) was by an unpaired two-tailed Student’s t test. 2
analysis was used to compare the number of animals
stepping in the open field followed by a one-sided Fish-
Table 1. Number of animals
WT (N) KO (N)
Long-term studies
SCI 21 24
BMS 21 24
Grid-walk 13 8
White matter sparing 11 8
Acute studies
Uninjured 7 7
SCI 19 19
Immunoblotting 8 8
Flow cytometry 18 18
Vehicle (N) Diclofenac (N)
Long-term studies
SCI (WT) 75 122
SCI (KO) 6 5
BMS 79 109
Grid walk 4 11
White matter sparing 14 28
Mortality (single dose) 2 1
Mortality (two doses) N/A 8
Mortality (three doses) N/A 9
Acute studies
In vitro 21 (pooled)
Uninjured 18 18
SCI 29 107
Flow cytometry 25 25
ELISA 17 95
Immunoblotting 5 5
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er’s exact test. Comparison of two groups was performed
by the Mann–Whitney test when at least one of the data-
sets failed the D’Agostino and Pearson omnibus normality
test. Statistical significance was defined at p 0.05. Data
are expressed as mean  SEM.
Data availability
All data are available from the authors.
Results
Functional recovery is improved in L-selectin KO mice
To assess whether L-selectin is a determinant of recovery
after SCI, we first compared locomotion of spinal cord-
injured L-selectin KO mice with WT littermate controls using
the BMS. L-selectin KO mice, subjected to SCI, showed a
marked improvement in locomotor recovery compared to
that of the WT group (p  0.006; Fig. 1A). A subsequent
secondary analysis revealed that 79.2% of KO animals
achieved weight supported plantar stepping (BMS  4)
compared to 47.6% of WT mice by 42 d post-SCI (p 
0.029; Fig. 1B). We also determined the number of foot-
faults of mice crossing a wire grid, which reflects sensori-
motor function and motor coordination (Schaar et al., 2010).
Foot-faults were reduced by 57.9% in the KO relative to the
WT group at 35 d post-SCI (p  0.023; Fig. 1C).
Functional recovery has been previously associated
with greater white matter sparing at the lesion epicenter
(Kuhn and Wrathall, 1998). To determine whether L-selectin
is associated with white matter damage, the percentage of
spared white matter was compared between groups in
transverse sections stained with LFB (Fig. 1D). Strikingly, the
percentage of spared white matter at the lesion epicenter
was 2.0-fold greater in the spinal cord-injured KO mice as
compared to injured WT mice at 42 d post-SCI (p  0.038;
Fig. 1E).
L-selectin is a determinant of oxidative stress in the
acutely injured cord
Newly recruited neutrophils and monocytes/macro-
phages from the blood promote oxidative stress in the
acutely injured cord (Lee et al., 2011). Since L-selectin is
expressed on blood neutrophils and monocytes, we ex-
amined the impact of the absence of L-selectin on oxida-
tive stress. Immunoblotting verified that MDA, a product
of lipid peroxidation (Liu et al., 2001) and marker for acute
oxidative stress (Esterbauer et al., 1991; Azbill et al., 1997;
Hichor et al., 2018), was similarly present at very low
levels in the uninjured spinal cords of mice of both geno-
types (p  0.98; Fig. 2). There was a 51% reduction in
MDA in injured L-selectin KO mice compared to injured
WT mice (p  0.026, 3 d post-SCI).
L-selectin is dynamically regulated on myeloid cells
following injury
In light of our findings with L-selectin KO mice, we
employed flow cytometry to quantify the expression of
L-selectin on circulating and spinal cord-infiltrated leuko-
cytes after SCI. Peripheral blood leukocytes from unin-
jured WT mice were also analyzed to establish baseline
L-selectin levels. Because of their prominent recruitment
during the acute phase of SCI (Beck et al., 2010), we
focused on myeloid cells (CD45/CD11b). We identified
Figure 1. L-selectin KO mice show improved functional recovery and greater white matter sparing at 42 d after SCI. A, Functional
recovery, as measured by the BMS open field test, was improved in KO mice. N  21 for WT and N  24 for KO combined from two
independent cohorts of mice. Two-way ANOVA (interaction p  0.11; time p  0.0001; genotype p  0.006; F(1,43)  8.42). B,
Stepping was improved in KO mice compared to WT mice. N  21 for WT and 24 for KO combined from two independent cohorts
of mice. 2 analysis followed by a one-sided Fisher’s exact test. p  0.029. C, Performance on a grid, as measured by foot faults,
was improved in the KO group. N  13 for WT and N  8 for KO. Two-tailed Student’s t test. p  0.023, t(19)  2.48. D,
Representative transverse sections at the lesion epicenter, stained with LFB, of injured WT and KO mice at 42 d post-SCI. Scale bar
 500 m. E, Greater spared white matter at the lesion epicenter, expressed as proportional area, was observed in the KO group.
N  11 for WT and N  8 for KO. Two-tailed Student’s t test. p  0.038, t(17)  2.26.
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leukocytes by gating for live (Ghost Dye-) CD45 cells,
then gated for myeloid cells (CD11b) and subdivided
them into neutrophils (Ly6Clow/Ly6G), inflammatory/
classical monocytes (Ly6Chi/L6G-), and patrolling/non-
classical monocytes (Ly6Clow/Ly6G-; Fig. 3A). For the
monocyte populations in peripheral blood, SCI resulted in
over 2-fold greater levels (G-MFI) of L-selectin (CD62L) on
Ly6Chi/L6G- cells at 24 and 72 h post-SCI (p  0.0001)
and an increase of 49.4% on Ly6Clow/L6G- cells at 72 h
post-SCI (p  0.048) compared to uninjured mice (Fig.
3B,C). In contrast, L-selectin decreased by 25.3% on
neutrophils (Ly6Clow/Ly6G cells) at 24 h post-SCI (p 
0.007) but returned to baseline (uninjured) values by 72 h
post-SCI. Leukocytes that accumulated in the spinal cord
parenchyma at 24 h post-SCI exhibited two to 5-fold
reduced levels of L-selectin on the myeloid subtypes
relative to levels on the corresponding cells in the blood
(Fig. 4A); however, considerable L-selectin remained on
the infiltrated cells for all subtypes, as established by
comparison with corresponding cells in KO mice (Fig.
4A) and isotype controls (Fig. 4B). These data demon-
strate that L-selectin is present in varying degrees on all
circulating myeloid lineages and is dynamically regu-
lated after SCI. Furthermore, considerable L-selectin is
retained on infiltrated myeloid cells, where it could
potentially be involved in post-recruitment adhesive or
signaling events.
L-selectin deficiency transiently reduces myeloid cell
accumulation in the spinal cord
As reviewed in the Introduction, L-selectin has been
implicated in the recruitment of myeloid cells in multiple
inflammatory settings. We therefore asked whether the
lack of L-selectin could reduce trafficking of myeloid cells
into the injured cord. We compared the number of leuko-
cytes in injured spinal cords of L-selectin KO and WT
mice. The accumulation of leukocytes in a particular tis-
sue reflects recruitment from the blood and their turnover
in the tissue. Using flow cytometry, we first determined
the total number of infiltrated myeloid lineage cells
(CD45/CD11b). We then used Ly6C and Ly6G antibod-
ies to discriminate neutrophils and monocyte/microglia
subtypes (Fig. 5A,B), and further subdivided the mono-
cyte and resident microglia populations based on CD45
levels. Few CD11b cells were detected in the spinal
cords of uninjured WT mice (650  103 cells) relative to
injured WT mice at 24 h post-SCI (13970  1920 cells). At
24 h post-SCI, very few infiltrated CD11b cells co-
labeled for T-cells (213  60 TCR cells) or B-cells (357
 113 B220 cells), confirming that CD11b cells were
predominantly myeloid cells. Furthermore, no differences
in CD45/CD11b- cells (lymphocytes) were observed in
the spinal cords of uninjured versus injured WT mice at 24
h post-SCI (485  186 vs 532  178 cells, p  0.87). At
24 h post-SCI, we observed reductions of 29.9% and
26.4% of CD11b cells (p  0.028) and Ly6Clow/L6G
cells (p  0.038), respectively, but no significant effects
on Ly6Chi/L6G- cells (p  0.10) or Ly6Clow/Ly6G- cells
(p  0.72) in the spinal cords of L-selectin KO mice
compared to WTs (Fig. 5A,C). Clearly, the decrease in
CD11b cells was mainly attributable to the Ly6Clow/
L6G cells (neutrophils), which comprised 72% of this
population. The contributions of L-selectin to myeloid cell
and neutrophil accumulation were limited in duration as
there were no differences in these populations between
KO and WT mice at 72 h post-SCI (Fig. 5B,D). No differ-
ences in the total number of CD11b/CD45low/L6G- cells
(microglia) were observed between WT and KO mice at 24
and 72 h post-SCI (p  0.10 and 0.38, respectively; Fig.
5E). No differences were observed in the proportion of
CD11b cells and myeloid lineage subsets among total
CD45 leukocytes in the peripheral blood of WT and KO
mice at 24 and 72 h post-SCI (p  0.25 for all subtypes;
Fig. 5F). In summary, we found that SCI was associated
with a massive influx of myeloid cells (21-fold increase)
into the spinal cord and the absence of L-selectin resulted
in a partial reduction in the accumulation of neutrophils at
24 h, which was not sustained through 72 h.
NSAIDS differentially induce L-selectin shedding on
murine leukocytes
As an alternative to the genetic ablation of L-selectin,
we sought a pharmacologic means to lower the cell
surface levels of this receptor. A major mechanism for
down-modulating L-selectin is through cleavage of the
membrane proximal domain of L-selectin by cell surface
metalloproteinases, such as ADAM17, causing the re-
lease (shedding) of the ligand-binding ectodomain into
Figure 2. L-selectin is a determinant of early oxidative stress in
the injured cord. Immunoblotting was performed on homoge-
nates of uninjured (UN) and injured (SCI) cords from WT and
L-selectin KOmice at 3 d post-SCI. All values were normalized to
-actin. By immunoblotting, MDA was reduced in L-selectin KO
mice by 51% compared to WT mice after SCI (p  0.026, t(8) 
2.73). N  3/genotype for UN and N  5/genotype for SCI.
Unpaired two-tailed Student’s t test. For UN, p  0.98, t(4) 
0.02.
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Figure 3. L-selectin is dynamically regulated after SCI. A, Flow cytometry gating of leukocytes and leukocyte subsets in the peripheral blood at
24and72hpost-SCI.B, Representative flowcytometry histograms forCD62Lstainingofmyeloid cells in theperipheral blood fromuninjuredmice
(gray line) and injured mice at 24 h (red line) and 72 h (blue line) post-SCI. Representative isotype staining is shown in solid black. C, L-selectin
(CD62L) levels on myeloid lineage cells in the peripheral blood from uninjuredWTmice, and injuredWTmice at 24 and 72 h post-SCI. N 4 for
UN,N 8 for 24 h, andN 6 for 72 h. One-way ANOVA with Tukey’s post hoc test (p 0.004,0.0001, 0.046, and 0.0001 and F(2,15) 7.97,
35.8, 3.80, and 17.7, respectively). p  0.05, p  0.01, p  0.001, p  0.0001.
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solution (Li et al., 2006). Certain NSAIDs can induce
L-selectin shedding in human leukocytes in vitro and in
vivo (Díaz-González et al., 1995), which led us to investi-
gate whether an NSAID could be used to down-modulate
L-selectin levels on myeloid cells during SCI and produce
benefit. We first performed in vitro experiments to test
NSAIDs for their ability to induce L-selectin shedding from
murine myeloid cells. We evaluated diclofenac and MFA,
which were shown to produce the most L-selectin shed-
ding in human leukocytes (Gómez-Gaviro et al., 2002).
Murine granulocytes (predominantly neutrophils), ex-
posed in vitro to either diclofenac or MFA, exhibited a
dose-dependent reduction in the level of L-selectin on the
cell surface (Fig. 6A,B).
The in vitro effects of a drug on particular leukocytes do
not necessarily predict its in vivo activities with critical
factors being the pharmacokinetics of the drug and the
turnover and anatomic compartmentalization of leuko-
cytes. To determine whether diclofenac induced the loss
of cell surface L-selectin in vivo, uninjured WT mice were
administered diclofenac (40 mg/kg, i.p.) and peripheral
blood leukocytes were evaluated 2, 8, or 24 h in separate
cohorts of mice for each time point. At 2 h post-injection,
increased L-selectin was detected on peripheral blood
CD11b cells from diclofenac-treated mice compared to
saline-treated mice (32.2% increase, p  0.03; Fig. 6C),
possibly due to mobilization of myeloid cells from the
bone marrow. At 8 h post-injection, there was a 38.3%
reduction of L-selectin on Ly6Clow/Ly6G cells (p 
0.0006; Fig. 6D) and a reduction of 26.3% at 24 h (p 
0.002; Fig. 6E).
Diclofenac improves long-term functional recovery
Having verified that diclofenac down-modulates L-
selectin levels on myeloid cells in vitro and in vivo, we
asked whether this drug could promote long-term recov-
ery after SCI. Mice were treated with a single dose (20, 30,
or 40 mg/kg) of diclofenac or vehicle (PBS) immediately
after SCI, and neurologic function was assessed using the
BMS open field test. We found considerable improvement
in locomotor recovery at the highest dose, but not at the
lower doses. Enhanced recovery was apparent by 7 d
post-SCI and persisted throughout the remainder of the
testing period (Fig. 7A). A subsequent secondary analysis
revealed that by day 35, 61.5% of WT mice treated with
40 mg/kg diclofenac were occasionally stepping as op-
posed to 0.0% of PBS-treated mice (p  0.002; Fig. 7B).
Diclofenac as an NSAID with a multiplicity of anti-
inflammatory activities (Scholer et al., 1986) could provide
benefit independently of its effects on L-selectin. To ad-
dress this issue, we compared neurologic recovery and
long-term white matter sparing in L-selectin KO mice
subjected to SCI and treated with 40 mg/kg diclofenac or
vehicle. As a positive control, we first examined diclofe-
nac in WTs and again observed improved long-term
neurologic recovery (Fig. 7C,D). We then examined
diclofenac- and vehicle-treated L-selectin KO mice and
found no differences based on the BMS scale (Fig. 7E).
The percentage of spared white matter was also quanti-
fied at the lesion epicenter (Fig. 7F,G). Diclofenac-treated
WT mice (40 mg/kg) showed 5-fold greater white matter
sparing compared to PBS-treated WT mice (p  0.030),
whereas there was no difference in white matter sparing in
KO mice treated with diclofenac versus PBS (p  0.70).
Thus, while diclofenac promoted recovery and neuropro-
tection in spinal cord-injured WTs, it provided no added
long-term benefit in the absence of L-selectin.
Diclofenac induces loss of L-selectin from specific
leukocyte subsets but does not affect leukocyte
accumulation in the injured spinal cord
We next determined whether diclofenac treatment af-
fected leukocyte accumulation after SCI. A single dose of
diclofenac (40 mg/kg) or vehicle (PBS) was given imme-
Figure 4. L-selectin is partially shed during infiltration into the spinal cord. A, L-selectin levels (G-MFI) on circulating and infiltrated
myeloid lineage cells from WT and KO mice at 24 h post-SCI. Background (isotype) values for CD62L were subtracted from each
datapoint so that the y-axis represents the specific signal. Autofluorescence resulted in a faint signal in non-classical monocytes in
the spinal cord but not in the blood of L-selectin KO mice. This was likely due to phagocytosed debris. N 8/group. One-way ANOVA
with Tukey’s post hoc test (p  0.0001 for each cell type and F(3,27)  5.49, 7.50, 4.71, and 7.92, respectively). p  0.01, p 
0.0001. B, Representative flow cytometry histograms for CD62L staining in leukocyte populations from the blood (white) and spinal
cord (gray) of WT mice at 24 h post-SCI. Representative isotype staining is shown in solid black.
New Research 9 of 18
July/August 2018, 5(4) e0101-18.2018 eNeuro.org
Figure 5. Leukocyte accumulation is transiently reduced in KO mice compared to WT mice after SCI. A, B, Flow cytometry gating of
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diately after SCI in WT mice. Peripheral blood and spinal
cords were harvested 24 h later, and flow cytometry was
performed to determine the levels of L-selectin as well as
the accumulation of leukocyte subsets in the cord (Fig.
8A). Peripheral blood was also acquired from uninjured
WT mice to compare basal expression levels of L-selectin
in circulating myeloid lineages. Consistent with the re-
sults above (Fig. 3B), at 24 h post-SCI, injury itself (with
saline injection) resulted in over 2-fold greater levels of
L-selectin on Ly6Chi/Ly6G- cells (p  0.005; Fig. 8B,D) in
blood. At 24 h post-SCI, diclofenac reduced L-selectin on
CD11b cells (38.2% reduction, p  0.004), Ly6Clow/
Ly6G- cells (34.6% reduction, p  0.022), and Ly6Clow/
Ly6G cells (41.1% reduction, p  0.005), but not on
Ly6Chi/Ly6G- cells (p  0.12) in blood of injured mice
compared to vehicle-treated controls (Fig. 8B,D). Impor-
tantly, diclofenac did not activate myeloid cells in the
blood (24 h post-SCI), as reflected by no change in
continued
leukocytes and leukocyte subsets in the injured spinal cord at A, 24 h and B, 72 h post-SCI. C, Accumulation of myeloid cells
(CD11b) and neutrophils (Ly6Clow/Ly6G), as determined by flow cytometry, was reduced in L-selectin KO compared to WT mice
at 24 h post-SCI (p  0.028 and 0.038, respectively). There were no differences in infiltrating inflammatory (Ly6Chi/Ly6G-, p  0.10)
or non-classical monocyte subsets (Ly6Clow/Ly6G-, p  0.72) between WT and KO mice. N  7 for WT and N  8 for KO.
Mann–Whitney test.D, There was no difference in the accumulation of any leukocyte subtype at 72 h post-SCI. N 6/group. Unpaired
two-tailed Student’s t tests. p  0.82, 0.81, 0.81, and 0.45 and t(10)  0.23, 0.25, 0.24, and 0.79, respectively. E, There were no
differences in microglia (CD11b/CD45low/Ly6G-) between WT and KO mice at 24 or 72 h post-SCI (p  0.10 and 0.38, respectively).
F, Prevalence of myeloid lineage subsets in the peripheral blood was similar between WT and KO mice at 24 and 72 h post-SCI.
N  7–8/genotype. Unpaired two-tailed Student’s t tests. No differences were detected (p  0.68, 0.25, 0.80, and 0.70 and t(13) 
0.42, 1.19, 0.25, and 0.40, respectively).
Figure 6. NSAIDs induce L-selectin shedding. A, CD62L flow cytometry histograms for WT or L-selectin KO granulocytes treated with
PMA or diclofenac (20 or 500 g/ml) and stained with an isotype control antibody (Iso Ctl) or a CD62L antibody. B, CD62L expression
(G-MFI) on WT murine granulocytes was reduced relative to vehicle (N  7) by treatment with diclofenac (N  5–6) and MFA (N 
4–6). N  3/group for KOs. Data were obtained from seven independent experiments. Cells were pooled from three mice for each
experiment (21 total mice). One-way ANOVA with Dunnett’s post hoc test. For diclofenac, p  0.0001 and F(4,24)  16.2. For MFA,
p  0.0001 and F(4,23)  10.0. p  0.05, p  0.01, p  0.001. C–E, CD62L expression (G-MFI) was reduced on neutrophils
(Ly6Clow/Ly6G) in uninjured mice receiving diclofenac relative to vehicle control at 8 and 24 h after injection. N  4/group at 8 h and
N  5/group at 2 and 24 h. Unpaired two-tailed Student’s t tests. p  0.031, 0.0006, and 0.002, and t(8)  2.61, t(6)  6.64, and
t(8)  4.52, respectively.
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CD11b levels (Fig. 8E). Thus, the actions of diclofenac do
not appear to be attributable to a generalized activation of
these cells.
No differences were apparent in the total numbers of
CD11b cells or myeloid lineage subsets in the spinal
cords of diclofenac-treated mice at 24 h post-SCI com-
pared to mice receiving the vehicle control (Fig. 8F). How-
ever, diclofenac reduced the level of L-selectin on
infiltrated CD11b cells (26.7% loss, p  0.020; Fig.
8C,G), Ly6Clow/Ly6G- cells (28.8% loss, p  0.008), and
Ly6Clow/Ly6G cells (31.8% loss, p  0.049). There was
no effect on Ly6Chi/Ly6G- cells (p  0.59). Thus, while
Figure 7. Long-term functional recovery and white matter sparing are improved in spinal cord-injured WT mice treated with diclofenac
immediately after injury. A, Spinal cord-injured mice treated with 40 mg/kg diclofenac showed improved recovery starting at 7 d
post-SCI as determined by the BMS open field test. N  10 for 30 mg/kg diclofenac, and N  13 for all other groups. Repeated
measures two-way ANOVA with Tukey’s post hoc test (interaction p  0.001; time p  0.001; treatment p  0.003 and F(3,45)  5.50).
p 0.0001 for vehicle versus 40 mg/kg diclofenac. No differences were observed between vehicle and 20 or 30 mg/kg diclofenac.
B, Stepping was improved in 40 mg/kg diclofenac-treated mice compared to mice receiving vehicle control. N  10 for 30 mg/kg
diclofenac, and N  13 for all other groups. 2 analysis followed by a one-sided Fisher’s exact test. p  0.006 for vehicle versus
40 mg/kg. p  0.006 for 20 versus 40 mg/kg and p  0.003 for 30 versus 40 mg/kg. C, Spinal cord-injured WT mice treated with 40
mg/kg diclofenac showed improved recovery compared to vehicle controls. N  10 for vehicle and N  11 for diclofenac. Repeated
measures two-way ANOVA with Sidak’s post hoc test (interaction p  0.001, time p  0.0001, treatment p  0.0004, and F(1,19) 
18.8). p  0.001, p  0.0001. D, The number of foot faults was reduced in diclofenac-treated mice. N  4 for PBS and N 
11 for diclofenac. Mann–Whitney test. p  0.0007. E, Functional recovery was similar between L-selectin KO mice treated with
diclofenac or vehicle (PBS). N  6 for PBS and N  5 for diclofenac. Repeated measures two-way ANOVA (interaction p  0.54, time
p  0.0001, treatment p  0.85 and F(1,9)  0.04). F, Representative images of the lesion epicenter, stained with LFB, in mice treated
with vehicle (PBS) or diclofenac. Scale bar  500 m. G, Spared white matter was increased in WT mice, but not L-selectin KO mice,
treated with diclofenac compared to vehicle (PBS) at 42 d post-SCI. Data are expressed as proportional area. N  4 for PBS-WT, N
 10 for diclofenac-WT, N  4 for PBS-KO, and N  6 for diclofenac-KO. Unpaired two-tailed Student’s t test. p  0.030 and t(12)
 2.46. For KO, p  0.70 and t(8)  0.40.
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diclofenac did not alter leukocyte accumulation in the
injured cord, L-selectin was reduced on the same myeloid
populations (i.e., neutrophils and non-classical mono-
cytes) in both the blood and spinal cord of injured
animals. To substantiate that diclofenac treatment re-
sulted in shedding of L-selectin from leukocytes, we
measured sL-selectin in blood plasma by ELISA. We
employed a single dose of diclofenac at increasing
doses (1, 5, 10, 20, 40, and 60 mg/kg) immediately
following SCI. Elevated sL-selectin (above vehicle
background) was detected at 8 and 24 h post-SCI with
40 and 60 mg/kg of diclofenac but not at the lower
doses (Fig. 8H). The elevation did not persist at 72 h
post-injection. Importantly, the high concentration of
Figure 8. Diclofenac treatment reduces L-selectin on peripheral blood and infiltrated leukocytes but does not alter accumulation in
the injured spinal cord. A, Flow cytometry gating for infiltrated myeloid cells and myeloid subsets. B, C, Representative flow cytometry
histograms for CD62L staining in leukocyte populations from the blood (B) or spinal cord (C) of vehicle-treated (white) and
diclofenac-treated (gray) mice at 24 h post-SCI. Representative isotype staining is shown in black. D, Flow cytometry analysis for
CD62L expression on peripheral blood leukocytes from uninjured mice and injured mice treated with diclofenac or vehicle (PBS).
Diclofenac induced a reduction of L-selectin on neutrophils and non-classical monocytes (p  0.005 and 0.02, respectively). N 
4/uninjured and N  6–7/SCI/treatment. One-way ANOVA with Tukey’s post hoc test (p  0.004, 0.0001, 0.019, and 0.0004 and
F(2,14)  8.47, 20.3, 5.30, and 14.8, respectively). p  0.05, p  0.01, p  0.001. E, Flow cytometry analysis for CD11b levels
on peripheral blood leukocytes from spinal cord-injured mice treated with diclofenac or vehicle (PBS). There were no differences in
CD11b levels on myeloid cells or myeloid lineage subsets. N  6–7/treatment. Unpaired two-tailed Student’s t tests. p  0.15, 0.47,
0.99, and 0.16 and t(11) 1.5, 0.75, 0.01, and 1.5, respectively. F, There were no differences in the accumulation of total myeloid cells
(CD11b) or any myeloid lineage subset in spinal cords of diclofenac-treated mice compared to vehicle-treated mice at 24 h post-SCI.
N  7/treatment. Unpaired two-tailed Student’s t tests. p  0.37, 0.53, 0.92, and 0.23 and t(12)  0.66, 0.64, 0.12, and 1.27,
respectively. G, Flow cytometry analysis demonstrated loss of L-selectin on total leukocytes (CD45, p 0.020 and t(12) 2.67), total
myeloid cells (CD11b, p  0.020 and t(12)  2.69), non-classical monocytes (Ly6C
low/Ly6G-, p  0.008 and t(12)  3.16), and
neutrophils (Ly6Clow/Ly6G, p  0.049 and t(12)  2.20) in the spinal cord of diclofenac-treated versus vehicle-treated mice at 24
h post-SCI. There was no effect on L-selectin on inflammatory monocytes (Ly6Chi/Ly6G-, p  0.59 and t(12)  0.56). N  7/treatment.
Unpaired two-tailed Student’s t tests. H, ELISA for sL-selectin in the peripheral blood at 8, 24, and 72 h post-SCI in mice receiving
a vehicle (PBS) control injection or 1–60 mg/kg of diclofenac. Increased sL-selectin was observed at 8 and 24 h, but not 72 h,
post-SCI in mice receiving 40 and 60 mg/kg diclofenac. N  5/group for 8 and 72 h; N  5/group at 24 h except for vehicle (N  7)
and 40 mg/kg diclofenac (N  10). One-way ANOVA followed by Dunnett’s post hoc test (p  0.005, 0.006, and 0.71 and F(6,28) 
4.05, F(6,35)  3.72, and F(6,28)  0.63, respectively). p  0.05, p  0.01.
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diclofenac required to induce L-selectin shedding par-
alleled the high concentration required to improve long-
term neurologic recovery (Fig. 7A).
Diclofenac reduces acute oxidative stress after SCI
Antibody-induced ligation of L-selectin has been shown
to induce or potentiate the production of ROS by neutro-
phils (Crockett-Torabi et al., 1995). Therefore, the reduced
level of L-selectin on these cells following diclofenac
treatment could potentially mitigate oxidative stress in the
acutely injured spinal cord. We therefore examined MDA
levels in the injured spinal cord at 72 h post-SCI in mice
receiving diclofenac (40 mg/kg) or vehicle (PBS) immedi-
ately following SCI. There was a 48.1% reduction in MDA
between diclofenac and vehicle-treated mice (p  0.045;
Fig. 9).
Diclofenac improves recovery when delivered within
3 h after SCI
To determine the window for the beneficial effects of
diclofenac, a single dose of diclofenac (40 mg/kg, i.p.)
was administered at 0, 3, or 8 h following SCI. Again, we
found that immediate delivery of diclofenac improved
long-term neurologic recovery of hindlimb function, as
seen by greater BMS scores within the first 7 d post-SCI
compared to vehicle-treated mice (Fig. 10A). Stepping
was also improved with 66.7% of diclofenac-treated mice
stepping at 42 d post-SCI compared to 7.7% of vehicle-
treated mice (p  0.003; Fig. 10D). When administration of
diclofenac was delayed for 3 h, improved neurologic recov-
ery was evident starting at 7 d post-SCI compared to time-
matched vehicle control mice (Fig. 10B). Although stepping
was not improved (38.5% vs 18.2%, p  0.26; Fig. 10E;
Table 2), white matter sparing was 2.3-fold greater in mice
receiving diclofenac at 3 h post-SCI compared to vehicle-
treated mice (p  0.011; Fig. 10G). There was no long-term
benefit in BMS scores or stepping when diclofenac treat-
ment was delayed to 8 h post-SCI (Fig. 10C,F).
To determine whether multiple doses of diclofenac con-
ferred additional benefit, we randomly grouped mice into
three cohorts and delivered diclofenac (40 mg/kg) at 0 h
(single dose), 0 and 24 h (two doses), or 0, 24, and 48 h
(three doses) post-SCI. Long-term neurologic benefit was
observed in the single and two-dose groups with im-
proved BMS scores starting at 7 d post-SCI compared to
the vehicle-treated group (Fig. 10H). No additional benefit
was observed for two doses compared to a single dose of
diclofenac. BMS scores could not be determined for mice
receiving three doses of diclofenac due to a high rate of
morbidity and mortality. While a single dose of diclofenac
exhibited a similar mortality rate to vehicle control injec-
tions, there was increased mortality for the double and
triple dose regimens (Fig. 10).
Discussion
The mechanisms underlying secondary pathogenesis,
including the pathogenic activities of myeloid cells, after
SCI are not fully understood, thereby limiting the devel-
opment of clinical therapies. This is the first study to
demonstrate the involvement of L-selectin in acute sec-
ondary pathogenesis in a murine model of SCI. We show
that the genetic ablation of L-selectin markedly improves
long-term neurologic recovery and white matter sparing.
Pursuing a pharmacologic approach to reduce L-selectin,
we demonstrate that the NSAID, diclofenac, induces par-
tial L-selectin shedding from mouse myeloid cells in vivo
and improves long-term neurologic outcomes when ad-
ministered up to 3 h following injury. Our findings provide
support for L-selectin shedding and the subsequent re-
duction of L-selectin-dependent activities other than my-
eloid cell recruitment, as an important anti-inflammatory
activity of diclofenac during SCI.
Past studies have achieved success in limiting inflam-
mation and secondary damage by targeting specific ad-
hesion molecules (such as P-selectin, CD11d/CD18, and
ICAM-1) and chemoattractants/chemokines involved in
the migration of peripheral leukocytes into the spinal cord
(Hamada et al., 1996; Taoka et al., 1997; Gonzalez et al.,
2003; Gris et al., 2004; Popovich and Longbrake, 2008;
Saiwai et al., 2010). In the present study, we have inves-
tigated L-selectin, which heretofore has not been consid-
ered in the context of SCI. A substantial body of evidence
has established that L-selectin functions as adhesion/
signaling molecule on myeloid cells and participates in
their recruitment and activation at inflammatory sites
(Lewinsohn et al., 1987; Pizcueta and Luscinskas, 1994;
Tedder et al., 1995; Stadtmann et al., 2013; Zuchtriegel
et al., 2015). We found considerable L-selectin levels
on all circulating myeloid cell subtypes, including neutro-
phils and monocytes, in uninjured WT mice. After SCI,
L-selectin was dynamically regulated on myeloid cells in
blood. Notably, there was a 25.3% reduction of L-selectin
on neutrophils 24 h after SCI, which may reflect a negative
feedback mechanism to attenuate L-selectin-dependent
inflammatory activities, as has been described in another
Figure 9. Diclofenac treatment reduces acute oxidative stress at
72 h post-SCI. By immunoblotting, MDA was reduced by 48.1%
in diclofenac-treated versus vehicle-treated WT mice after SCI
(p  0.045, t(8)  2.37). N  5/treatment. Unpaired two-tailed
Student’s t test. All values were normalized to GAPDH.
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setting of injury and inflammation (Strausbaugh et al.,
1999). Reduced L-selectin has been previously observed
in circulating neutrophils in spinal cord-injured human
patients (Bao et al., 2008); however, this study also found
reduced L-selectin levels on circulating monocytes. The
increase in L-selectin on circulating monocyte popula-
tions in our study in mouse may reflect species differences in
L-selectin regulation during inflammatory responses to SCI.
Figure 10. Diclofenac treatment improves long-term recovery when delayed for 3 h, but not 8 h, post-SCI. A, BMS scores
demonstrated improved neurologic recovery when diclofenac was delivered immediately following injury. N  13 for vehicle and N
 12 for diclofenac. Two-way ANOVA with Sidak’s post hoc test (interaction p  0.0001, time p  0.0001, treatment p  0.0001 and
F(1,23)  26.0). p  0.05, p  0.01, p  0.001, p  0.0001. B, Recovery was also improved when administration of
diclofenac was delayed to 3 h post-SCI. N  11 for vehicle and N  13 for diclofenac. Two-way ANOVA with Sidak’s post hoc test
(interaction p  0.0001, time p  0.0001, treatment p  0.0005 and F(1,22)  17.0). p  0.05, p  0.01, p  0.001. C, No
improvement was observed when diclofenac was delayed to 8 h post-SCI. N  13 for vehicle and N  10 for diclofenac. Two-way
ANOVA with Sidak’s post hoc test (interaction p  0.42, time p  0.001, treatment p  0.23 and F(1,21)  1.51). D, Improved stepping
ability was observed when diclofenac was delivered immediately after injury. 2 analysis followed by a one-sided Fisher’s exact test.
N  13 for vehicle and N  12 for diclofenac. p  0.003. E, No benefit for stepping was observed when diclofenac was delivered
3 h after injury. 2 analysis followed by a one-sided Fisher’s exact test. N  11 for vehicle and N  13 for diclofenac. p  0.26. F,
No benefit for stepping was observed with an 8-h delay of diclofenac administration. 2 analysis followed by a one-sided Fisher’s
exact test. N  13 for vehicle and N  10 for diclofenac. p  0.69. G, Spared white matter at the lesion epicenter was increased at
42 d post-SCI in WT mice treated with diclofenac at 3 h post-SCI compared to the time-matched vehicle (PBS) control group. Data
are expressed as total area. N  6 for PBS and N  12 for diclofenac. Two-tailed Student’s t test. p  0.011, t(16)  2.87. H, No
additional benefit in BMS score was achieved by administering a second dose of diclofenac. N  13 for vehicle, N  15 for single
dose, and N  7 for two doses. Two-way ANOVA with Tukey’s post hoc test (interaction p  0.001, time p  0.001, treatment p 
0.002 and F(2,32) 8.04). p 0.55 for single versus two doses for all timepoints. p 0.05, p 0.01, p 0.001. I, Multiple doses
of diclofenac resulted in higher mortality rates.
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L-selectin deficiency was associated with partially re-
duced neutrophil accumulation into the acutely injured
spinal cord (24 h post-SCI). This is consistent with the
participation of L-selectin in recruitment of neutrophils,
e.g., as an adhesive molecule in secondary tethering to
other leukocytes or as a signaling molecule in activating
integrins on neutrophils (Walcheck et al., 1996; Zarbock
et al., 2011; Stadtmann et al., 2013; Morikis et al., 2017).
At 72 h post-SCI, when neutrophil numbers in the cord
were3-fold fewer than at 24 h (reflecting death or exit of
the infiltrated neutrophils), there was no difference be-
tween WT and KO mice. However, at the same time point,
we did find reduced oxidative stress in the acutely injured
cord of L-selectin KO mice, suggesting the possibility of
ROS as a component of L-selectin mediated pathogene-
sis. Many studies have established a role for L-selectin in
modulating the internal signaling and secretome of neu-
trophils (Zarbock and Ley, 2008), including the potentia-
tion of ROS production (Crockett-Torabi et al., 1995).
Elucidation of the signaling pathways by which L-selectin
contributes to ROS production after SCI could identify
novel targets to reduce acute secondary pathogenesis.
Myelin sheaths of CNS, but not peripheral nervous
system, express ectopic ligands (presumed to be car-
bohydrate-based and structurally related to true biologi-
cal ligands) for L-selectin that are sufficient to support
leukocyte adhesion in an in vitro assay (Huang et al.,
1991; Huang et al., 1994). We found that neutrophils that
infiltrated the injured spinal cord at 24 and 72 h post-SCI
retained 19.2% and 14.8% of L-selectin levels, respec-
tively, relative to those in peripheral blood. These levels
are still appreciable, since L-selectin is normally present
at high density on blood leukocytes (105 molecules/cell;
Simon et al., 1992). Infiltrating neutrophils and monocytes
could potentially interact with these “illegitimate” ligands
via L-selectin to facilitate activation of effector functions
that promote myelin degradation, a mechanism that has
been invoked in a model of experimental allergic enceph-
alitis (Grewal et al., 2001). Notably, engagement of L-se-
lectin on neutrophils with incidental carbohydrate ligands
(carcinoma or saliva mucins) potentiates the degranula-
tion of these cells (Shao et al., 2011), even after consid-
erable shedding of L-selectin (Mohanty et al., 2015). Thus,
reduced L-selectin on spinal cord-infiltrated neutrophils
may still be sufficient to drive post-recruitment activities.
NSAIDs are a heterogeneous group of compounds that
continue to be an important intervention in patients with
non-severe inflammatory disorders. Several NSAIDs
provide neuroprotection in experimental models of SCI
(Kwon et al., 2011). In the present study, we show that
administration of diclofenac led to marked improvements
in long-term recovery and sparing of white matter after
SCI. The beneficial effects of diclofenac treatment follow-
ing SCI were comparable to those seen in L-selectin KO
mice. Our study thus adds diclofenac, a widely prescribed
medication (Altman et al., 2015), to the group of NSAIDs
that are beneficial in SCI.
We were initially drawn to diclofenac because it belongs
to the subgroup of NSAIDs that are capable of inducing a
high level of L-selectin shedding from the surface of
leukocytes (Díaz-González et al., 1995; Gómez-Gaviro
et al., 2002). In the present study, diclofenac induced the
loss of L-selectin in non-classical monocytes and neutro-
phils within the blood and spinal cord of injured mice. Our
report is the first to show a differential effect of NSAIDs on
loss of L-selectin from monocyte subtypes with non-
classical monocytes being the susceptible population in
the context of SCI. The diclofenac-induced reduction in
L-selectin on non-classical monocytes could potentially
impact signaling by these cells and diminish their delete-
rious activities in SCI (Donnelly et al., 2011). With respect
to neutrophils, the diclofenac-induced reduction of
L-selectin levels was not accompanied by reduced accu-
mulation in the injured spinal cord (24 h), which contrasts
with the observations in L-selectin KO mice at this time
point. This difference may be ascribed to the fact that
diclofenac treatment resulted in only a partial loss of
L-selectin. Nonetheless, the diclofenac treatment reduced
oxidative stress at 72 h post-SCI, an effect that could
plausibly be a consequence of reduced signaling and
degranulation of neutrophils, as detailed above.
The anti-inflammatory activities of NSAIDs are usually
attributed to inhibition of cyclooxygenase (COX), a key
enzyme for prostaglandin production. However, Sánchez-
Madrid, Díaz-González, and co-workers have also high-
lighted L-selectin shedding from neutrophils as a potential
anti-inflammatory action of certain NSAIDs (Herrera-
García et al., 2013; Díaz-González and Sánchez-Madrid,
2015). In our experiments, we cannot exclude that the
benefit of diclofenac is due to COX inhibition or di-
clofenac-induced shedding of molecules other than
L-selectin. However, our finding of equivalent neurologic
outcomes after SCI in L-selectin KO mice, treated with
diclofenac compared to the vehicle control group, sug-
gests that the beneficial effect of diclofenac is related to
its ability to induce L-selectin shedding. Taken together,
our diclofenac findings are consistent with the possibility
that the partial loss of L-selectin induced by this drug
reduces the deleterious activities of myeloid cells in sec-
ondary pathogenesis. Further mechanistic studies are
Table 2. Categorical analysis of BMS scoring
Vehicle (3 h post-SCI, N  11) Diclofenac (3 h post-SCI, N  13)
BMS category 1 d 7 d 42 d 1 d 7 d 42 d
0 100% (11) 27.3% (3) 100% (13) 7.7% (1)
1 45.5% (5) 27.3% (3) 38.5% (5)
2 27.3% (3) 45.5% (5) 15.4% (2) 30.8% (4)
3 9.1% (1) 38.5% (5) 30.8% (4)
4 18.2% (2) 7.7% (1)
5 30.8% (4)
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needed to substantiate this scenario as opposed to other
potential activities of diclofenac.
In our experiments, 40 mg/kg of diclofenac was re-
quired to improve long-term neurologic recovery after
SCI, but repeated dosing at this high level was associated
with increased mortality. According to the FDA’s guide-
lines for conversion to a human equivalent dose (Nair and
Jacob, 2016), the dose for a 60-kg individual would be
3.25 mg/kg. In fact, oral administration of diclofenac to
human subjects at a dose of 2.5 mg/kg/d has been
shown to promote robust loss of L-selectin on blood
neutrophils (Baranda, 1998). Thus, it would be feasible to
test diclofenac for efficacy in human SCI at an FDA-
approved dose. Evaluation of diclofenac in the context of
sex as a biological variable will be an important factor in
such studies.
Our findings establish a therapeutic window for diclofenac
administration with efficacy observed up to at least 3 h, but
8 h, after SCI. This timeframe is consistent with our obser-
vations that the pathologic contributions of L-selectin are
associated with early myeloid cell activities (72 h post-
SCI). Recent clinical studies have also highlighted the
importance of early intervention with anti-inflammatory strat-
egies (Ahuja et al., 2016). Future exploration of more clini-
cally relevant methods for delivery of diclofenac and
development of faster acting structural analogues with im-
proved safety profiles may extend the therapeutic window
for strategies targeting L-selectin after SCI.
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